Operational Costs Compared: SG&A Analysis of Amgen Inc. and Novavax, Inc.

A Decade of SG&A: Amgen Inc. vs. Novavax, Inc.

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Amgen Inc. and Novavax, Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Amgen, a biotech giant, consistently maintained high SG&A expenses, peaking at approximately $6.2 billion in 2023, reflecting its expansive global operations and robust marketing strategies. In contrast, Novavax, a smaller player, saw a dramatic rise in SG&A expenses, surging over 2,200% from 2014 to 2023, as it scaled operations to meet pandemic-driven demand. This divergence highlights the strategic choices companies make in resource allocation, with Amgen focusing on steady growth and Novavax on rapid expansion. As the industry continues to adapt to new challenges, understanding these financial dynamics offers valuable insights into corporate strategy and market positioning.